Difference between revisions of "Fluvoxamine-doxepine"
From Psychiatrienet
| Line 2: | Line 2: | ||
| from = fluvoxamine | | from = fluvoxamine | ||
| to = doxepin | | to = doxepin | ||
| − | | stop = | + | | stop = {{StopSSRI,SNRI}} |
| − | {{ | ||
| start = | | start = | ||
| − | * '''Day 1:''' | + | * '''Day 1:''' start administration of doxepine in a low dosage of 25mg/day. |
| − | * '''Day 8:''' | + | * '''Day 8:''' increase dosage of doxepine to a dosage of 75 mg/day. |
| info = | | info = | ||
| − | * | + | * fluvoxamine slows the metabolism of doxepine via CYP2C19 inhibition. |
| − | * | + | * {{SSCYPinh}} |
| + | * {{TCAplasmalevelmonitoring}} | ||
Revision as of 15:40, 30 June 2023
{{Drugswitch | from = fluvoxamine | to = doxepin | stop =
- Day 1: Decrease dose to 50%
- Day 8: Stop
| start =
- Day 1: start administration of doxepine in a low dosage of 25mg/day.
- Day 8: increase dosage of doxepine to a dosage of 75 mg/day.
| info =
- fluvoxamine slows the metabolism of doxepine via CYP2C19 inhibition.
- Due to CYP inhibition a longer period of time is needed to reach steady state concentration. Please keep in mind when monitoring plasma levels
- Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.[1]
